Adelene Perkins, Infinity CEO

Could a fourth lead drug fi­nal­ly bring In­fin­i­ty an ap­proval?

Maybe fourth time’s the charm?

In­fin­i­ty Phar­ma­ceu­ti­cals, the thrice-failed on­col­o­gy biotech, an­nounced up­dat­ed da­ta Tues­day from its new lead drug in a pair of can­cers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.